Tikun Olam-Cannbit Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Tikun Olam-Cannbit Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-4.9%
Buyback Yield
| Total Shareholder Yield | -4.9% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Tikun Olam-Cannbit Pharmaceuticals Ltd's (TLV:TKUN) Popularity With Investors Under Threat As Stock Sinks 26%
Dec 02
Health Check: How Prudently Does Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Use Debt?
Oct 23Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Has Debt But No Earnings; Should You Worry?
Jun 21Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 28Risks To Shareholder Returns Are Elevated At These Prices For Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN)
Jul 21Would Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Be Better Off With Less Debt?
Oct 03Is Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Weighed On By Its Debt Load?
Jun 03Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Is Carrying A Fair Bit Of Debt
Oct 17Is Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Using Debt Sensibly?
May 19Shareholders Of Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Must Be Happy With Their 135% Total Return
Mar 19How Much Did Tikun Olam - Cannbit Pharmaceuticals'(TLV:TKUN) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 02
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if TKUN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TKUN's dividend payments have been increasing.
Dividend Yield vs Market
| Tikun Olam-Cannbit Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (TKUN) | n/a |
| Market Bottom 25% (IL) | 2.2% |
| Market Top 25% (IL) | 6.0% |
| Industry Average (Pharmaceuticals) | 1.8% |
| Analyst forecast (TKUN) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate TKUN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TKUN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate TKUN's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TKUN has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 17:53 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tikun Olam-Cannbit Pharmaceuticals Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|